Alimera Sciences, Inc. (ALIM): Price and Financial Metrics

Alimera Sciences, Inc. (ALIM): $3.16

-0.11 (-3.36%)

POWR Rating

Component Grades













ALIM Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for ALIM is -2.99 -- better than only 3.69% of US stocks.
  • ALIM's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.33 -- higher than merely 3.55% of US-listed equities with positive expected earnings growth.
  • ALIM's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 3.49% of US stocks.
  • Stocks that are quantitatively similar to ALIM, based on their financial statements, market capitalization, and price volatility, are CLRO, NEON, CMCM, KNDI, and BKYI.
  • Visit ALIM's SEC page to see the company's official filings. To visit the company's web site, go to

ALIM Valuation Summary

  • ALIM's EV/EBIT ratio is -4.9; this is 160.49% lower than that of the median Healthcare stock.
  • ALIM's EV/EBIT ratio has moved up 6.7 over the prior 154 months.

Below are key valuation metrics over time for ALIM.

Stock Date P/S P/B P/E EV/EBIT
ALIM 2022-12-05 0.5 -1.4 -1.3 -4.9
ALIM 2022-12-02 0.5 -1.4 -1.4 -5.0
ALIM 2022-12-01 0.4 -1.3 -1.3 -4.9
ALIM 2022-11-30 0.4 -1.3 -1.3 -4.9
ALIM 2022-11-29 0.5 -1.4 -1.3 -4.9
ALIM 2022-11-28 0.4 -1.3 -1.3 -4.9

ALIM Growth Metrics

    Its year over year net cashflow from operations growth rate is now at -32.32%.
  • The 5 year net cashflow from operations growth rate now stands at 84.51%.
  • The 4 year cash and equivalents growth rate now stands at -60.42%.
ALIM's revenue has moved up $19,726,000 over the prior 70 months.

The table below shows ALIM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 54.059 -14.407 -18.433
2022-06-30 52.614 -15.226 -17.359
2022-03-31 59.713 -6.936 -6.679
2021-12-31 59.029 -3.224 -4.372
2021-09-30 58.844 1.196 -1.243
2021-06-30 59.164 1.78 2.322

ALIM Price Target

For more insight on analysts targets of ALIM, see our ALIM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.83 Average Broker Recommendation 1.5 (Moderate Buy)

ALIM Stock Price Chart Interactive Chart >

Price chart for ALIM

ALIM Price/Volume Stats

Current price $3.16 52-week high $7.92
Prev. close $3.27 52-week low $3.11
Day low $3.11 Volume 15,100
Day high $3.27 Avg. volume 22,307
50-day MA $4.81 Dividend yield N/A
200-day MA $5.49 Market Cap 22.11M

Alimera Sciences, Inc. (ALIM) Company Bio

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States, Germany, the United Kingdom, and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through direct sales and distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.

ALIM Latest News Stream

Event/Time News Detail
Loading, please wait...

ALIM Latest Social Stream

Loading social stream, please wait...

View Full ALIM Social Stream

Latest ALIM News From Around the Web

Below are the latest news stories about ALIMERA SCIENCES INC that investors may wish to consider to help them evaluate ALIM as an investment opportunity.

Alimera Highlights Abstracts Regarding Consensus Among US Retina Specialists and Reduced Retinal Thickness Variability Leading to Improved Visual Outcomes Following ILUVIEN® Administration

Data was included in scientific programming at the annual meeting of The Retina SocietyATLANTA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announces findings from a recent meeting where data demonstrated a high level of agreement among retina specialists on the role of inflammation in

Yahoo | November 29, 2022

7 Stocks That Could Implode at Any Moment

Although it’s a party-pooper topic, the vagaries of the market dictates that investors should be aware of these stocks to sell.

Josh Enomoto on InvestorPlace | November 17, 2022

Alimera Sciences Third Quarter 2022 Earnings: Misses Expectations

Alimera Sciences ( NASDAQ:ALIM ) Third Quarter 2022 Results Key Financial Results Revenue: US$13.6m (up 12% from 3Q...

Yahoo | November 16, 2022

H.C. Wainwright Sticks to Its Buy Rating for Alimera (ALIM)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Alimera (ALIM - Research Report), with a price target of $9.00. The company's shares closed yesterday at $4.88.According to TipRanks, Chen is an analyst with an average return of -28.1% and a 24.40% success rate. Chen covers the Healthcare sector, focusing on stocks such as Veru, Applied DNA Sciences, and Aslan Pharmaceuticals.Alimera has an analyst consensus of Moderate Buy, with a price target consensus of $9.00.See today’s best-performing stocks on TipRanks >>Based on Alimera's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $14.

Austin Angelo on TipRanks | November 15, 2022

Alimera Sciences (ALIM) Reports Q3 Loss, Lags Revenue Estimates

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -102.70% and 12.83%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 14, 2022

Read More 'ALIM' Stories Here

ALIM Price Returns

1-mo -33.89%
3-mo -52.55%
6-mo -41.04%
1-year -32.04%
3-year -66.53%
5-year -83.79%
YTD -38.40%
2021 21.56%
2020 -44.33%
2019 -29.62%
2018 -46.02%
2017 23.15%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7507 seconds.